{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:44:32Z","timestamp":1793281472877,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg\/kg in Chinese patients with acute ischemic stroke (AIS) is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To establish the noninferiority of tenecteplase to alteplase in patients with AIS within 4.5 hours of symptom onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The ORIGINAL study was a multicenter, active-controlled, parallel-group, randomized, open-label, blinded end point, noninferiority trial conducted between July 14, 2021, and July 14, 2023. Participants were recruited from 55 neurology clinics and stroke centers in China and were eligible if they had AIS with a National Institutes of Health Stroke Scale score of 1 to 25 with measurable neurologic deficit and were symptomatic for at least 30 minutes without significant improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized (1:1) within 4.5 hours of symptom onset to receive intravenous tenecteplase (0.25 mg\/kg) or intravenous alteplase (0.9 mg\/kg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0 or 1 (no symptoms or no significant disability) at day 90, tested for noninferiority (risk ratio [RR] margin, 0.937). Safety end points included symptomatic intracerebral hemorrhage (per European Cooperative Acute Stroke Study III definition) and 90-day all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 1489 patients randomized, 1465 patients were included in the full analysis set (732 in the tenecteplase group; 733 in the alteplase group) and 446 (30.4%) were female. The primary outcome occurred in 72.7% (532\/732) of patients receiving tenecteplase and 70.3% (515\/733) receiving alteplase (RR, 1.03 [95% CI, 0.97-1.09]; noninferiority threshold met). Symptomatic intracerebral hemorrhage occurred in 9 patients (1.2%) in each group (RR, 1.01 [95% CI, 0.37-2.70]). The 90-day mortality rate was 4.6% (34\/732) in the tenecteplase group and 5.8% (43\/736) in the alteplase group (RR, 0.80 [95% CI, 0.51-1.23]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In patients with AIS eligible for intravenous thrombolysis within 4.5 hours after stroke onset, tenecteplase was noninferior to alteplase with respect to excellent functional outcome (mRS score of 0 or 1) at 90 days and had a similar safety profile. Findings from this study support tenecteplase as a suitable alternative to alteplase in this setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04915729\">NCT04915729<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.14721","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:06:32Z","timestamp":1726153592000},"page":"1437","source":"Crossref","is-referenced-by-count":116,"title":["Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke"],"prefix":"10.1001","volume":"332","author":[{"given":"Xia","family":"Meng","sequence":"first","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing"},{"name":"Departments of Neurology and Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Li","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing"},{"name":"Departments of Neurology and Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongguo","family":"Dai","sequence":"additional","affiliation":[{"name":"Linfen Central Hospital, Linfen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Lu","sequence":"additional","affiliation":[{"name":"Hexigten Banner Mongolian Traditional Chinese Medicine Hospital, Chifeng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Xianyang Hospital of Yan\u2019an University, Xianyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Che","sequence":"additional","affiliation":[{"name":"Linyi People\u2019s Hospital, Linyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Geng","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial People\u2019s Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyan","family":"Li","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing"},{"name":"Departments of Neurology and Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing"},{"name":"Departments of Neurology and Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"joi240096r1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"20","author":"Stroke Collaborators GBD","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"joi240096r2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/17474930221135983","article-title":"Increasing burden of stroke in China: a systematic review and meta-analysis of prevalence, incidence, mortality, and case fatality.","volume":"18","author":"Zhao","year":"2023","journal-title":"Int J Stroke"},{"issue":"1","key":"joi240096r3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40779-023-00463-x","article-title":"China stroke surveillance report 2021.","volume":"10","author":"Tu","year":"2023","journal-title":"Mil Med Res"},{"issue":"12","key":"joi240096r4","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"1","key":"joi240096r5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J"},{"issue":"6","key":"joi240096r6","article-title":"Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update.","volume":"8","author":"Liu","year":"2023","journal-title":"Stroke Vasc Neurol"},{"issue":"15","key":"joi240096r9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"joi240096r10","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator.","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9180","key":"joi240096r11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.","volume":"354","author":"Van De Werf","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"joi240096r12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","article-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.","volume":"366","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"joi240096r13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"joi240096r14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1747493017733935","article-title":"Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study.","volume":"13","author":"Campbell","year":"2018","journal-title":"Int J Stroke"},{"issue":"10347","key":"joi240096r15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"joi240096r16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/svn-2021-000978","article-title":"Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol"},{"issue":"10377","key":"joi240096r17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"joi240096r18","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.124.001363","article-title":"Tenecteplase versus alteplase in acute ischemic stroke in Chinese patients: protocol for the ORIGINAL study.","author":"Meng","year":"2024","journal-title":"Stroke Vasc Interv Neurol"},{"issue":"9","key":"joi240096r19","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","article-title":"Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale.","volume":"33","author":"Wilson","year":"2002","journal-title":"Stroke"},{"issue":"13","key":"joi240096r20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"joi240096r21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"joi240096r22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/svn-2020-000337","article-title":"Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.","volume":"5","author":"Zheng","year":"2020","journal-title":"Stroke Vasc Neurol"},{"issue":"7","key":"joi240096r23","doi-asserted-by":"publisher","first-page":"e2325415","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial.","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9958","key":"joi240096r25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"joi240096r26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0962280211427759","article-title":"Extension of the modified Poisson regression model to prospective studies with correlated binary data.","volume":"22","author":"Zou","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"joi240096r28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fneur.2018.00308","article-title":"Prediction of outcome in patients with acute ischemic stroke based on initial severity and improvement in the first 24 h.","volume":"9","author":"Wouters","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"joi240096r29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.53.1.126","article-title":"Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).","volume":"53","author":"Adams","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"joi240096r31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/17474930231154390","article-title":"Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): a multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.","volume":"18","author":"Bivard","year":"2023","journal-title":"Int J Stroke"},{"issue":"9558","key":"joi240096r32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"issue":"9136","key":"joi240096r33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"joi240096r34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset.","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"joi240096r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100406","article-title":"Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020.","volume":"21","author":"Ye","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"joi240096r36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/svn-2019-000242","article-title":"The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics.","volume":"4","author":"Wang","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"joi240096r7","unstructured":"Genentech Inc. TNKase (tenecteplase) US prescribing information. March 2023. Accessed July 12, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103909s5194lbl.pdf"},{"key":"joi240096r8","unstructured":"Boehringer Ingelheim International GmbH. Metalyse (tenecteplase) EU summary of product characteristics. January 2023. Accessed November 1, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/metalyse-epar-product-information_en.pdf"},{"key":"joi240096r24","unstructured":"US Department of Health and Human Services. Guidance document: non-inferiority clinical trials (FDA-2010-D-0075). August 24, 2018. Accessed July 12, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/non-inferiority-clinical-trials"},{"key":"joi240096r27","unstructured":"Muir? K, Ford? G, Ford? I, . Tenectplase versus alteplase for acute stroke within 4.5h of onset: the second alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST-2). Paper presented at: World Stroke Congress 2023; October 10-12, 2023; Toronto, Canada. Accessed July 12, 2024. https:\/\/journals.sagepub.com\/doi\/10.1177\/17474930231201072"},{"key":"joi240096r30","unstructured":"Boehringer Ingelheim International GmbH. Actilyse (alteplase for injection) package insert. 2020. Accessed July 12, 2024. https:\/\/www.boehringer-ingelheim.com\/human-health\/products\/actilyser"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2823655\/jama_meng_2024_oi_240096_1730411776.65204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:04:18Z","timestamp":1730822658000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2823655"}},"subtitle":["The ORIGINAL Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":36,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,11,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.14721","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}